EP1651273A1 - Poly-4-hydroxybutyrate matrices for sustained drug delivery - Google Patents

Poly-4-hydroxybutyrate matrices for sustained drug delivery

Info

Publication number
EP1651273A1
EP1651273A1 EP04777860A EP04777860A EP1651273A1 EP 1651273 A1 EP1651273 A1 EP 1651273A1 EP 04777860 A EP04777860 A EP 04777860A EP 04777860 A EP04777860 A EP 04777860A EP 1651273 A1 EP1651273 A1 EP 1651273A1
Authority
EP
European Patent Office
Prior art keywords
drug
delivery system
drug delivery
hydroxybutyrate
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04777860A
Other languages
German (de)
French (fr)
Other versions
EP1651273B1 (en
Inventor
Vasif N. Hasirci
Dilek Keskin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tepha Inc
Original Assignee
Tepha Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tepha Inc filed Critical Tepha Inc
Publication of EP1651273A1 publication Critical patent/EP1651273A1/en
Application granted granted Critical
Publication of EP1651273B1 publication Critical patent/EP1651273B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • the present invention generally relates to drug delivery systems derived from poly-4-hydroxybutyrate.
  • the use of biodegradable polymers to make drug delivery systems is well established.
  • Berde and Langer have also reported drawbacks of certain degradable polyanhydride drug delivery systems that include fast initial release of drug, and inflammatory responses to the device or the formation of a capsule of serous material or fibrin.
  • certain applications such as the treatment of chronic or persistent pain, long- term contraception or administration of antibiotics, growth factors, or chemotherapeutics, or prevention of restenosis after stent implantation, it would be advantageous to develop systems that can administer drugs for prolonged periods of time.
  • Biodegradable controlled release systems providing prolonged controlled release of drugs, and methods for the manufacture thereof are disclosed.
  • the systems are formed from a biocompatible, biodegradable polymer, in particular poly-4-hydroxybutyrate (PHA440) or copolymers thereof.
  • Copolymers of 4-hydroxybutyrate include but are not limited to poly-3-hydroxybutyrate-co-4-hydroxybutyrate (PHA3444), and poly-4- hydoxybutyrate-co-glycolate (PHA4422).
  • Drugs are generally incorporated into the polymer using a method that yields a uniform dispersion. The type of drug and the quantity are selected based on the known pharmaceutical properties of these compounds.
  • the systems may be administered for example by implantation, injection, topical administration, or oral ingestion. They may also be used in combination with a medical device, for example, a stent.
  • a medical device for example, a stent.
  • a major advantage of the drug delivery system is that it does not need to be removed after use since it is slowly degraded and cleared by the patient's body.
  • the device has desirable physical properties, including strength, modulus and elongation.
  • Figures 1A and IB are the chemical structures of poly-4- hydroxybutyrate (PHA4400) and poly-3-hydroxybutyrate-co-4- hydroxybutyrate (PHA3444).
  • Figure 2 is sdescription of the biosynthetic pathways for the production of PHA4400 (P4HB). Pathway enzymes are: 1.
  • Figure 3A Average cumalative (%) release vs. time;
  • Figure 3B Average Cum. (%) release vs. square root time .
  • Figure 4A Average Cum. (%) release vs. time;
  • Figure 4B Average Cumulative (%) release vs. square root time.
  • Figures 5 A and 5B are graphs of the release of Tetracycline from
  • FIG. 1 shows Average Cumulative (%) release versus time;
  • Figure 5B shows Average Cumulative (%) release versus square root time.
  • Figure 6A shows Average Cumulative (%) release versus time
  • Figure 6B shows Average Cumulative (%) release versus square root time.
  • Biodegradable drug delivery systems for the controlled and prolonged release of drugs are provided. These systems can be used where it is necessary to administer a controlled amount of drug over a prolonged period, and/or to employ a system requiring a high drug loading.
  • Poly-4-hydroxybutyrate means a homopolymer comprising 4- hydroxybutyrate units. It may be referred to as PHA4400 or P4HB.
  • Copolymers of poly-4-hydroxybutyrate mean any polymer comprising 4- hydroxybutyrate with one or more different hydroxy acid units, for example, poly-3-hydroxybutyrate-co-4-hydroxybutyrate (PH3444).
  • Biocompatible refers to materials that are not toxic, and do not elicit severe inflammatory or chronic responses in vivo. Any metabolites of these materials should also be biocompatible.
  • Biodegradation means that the polymer must break down or dissolve away in vivo, preferably in less than two years, and more preferably in less than one year. Biodegradation refers to a process in an animal or human. The polymer may break down by surface erosion, bulk erosion, hydrolysis or a combination of these mechanisms.
  • microspheres also includes nanospheres, microparticles, and microcapsules.
  • Drug Delivery Devices A. Polymers Poly-4-hydroxybutyrate (PHA4400) is a strong, pliable thermoplastic that is produced by a fermentation process (see US Patent No.
  • the polymer belongs to a larger class of materials called polyhydroxyalkanoates (PHAs) that are produced by numerous microorganims (for reviews see: Steinb ⁇ chel, A. (1991) Polyhydroxyalkanoic acids, in Biomaterials, (Byrom, D., Ed.), pp.
  • PHAs polyhydroxyalkanoates
  • PHAs Polyhydroxyalkanoates
  • the PHA biopolymers may be broadly divided into three groups according to the length of their pendant groups and their respective biosynthetic pathways. Those with short pendant groups, such as polyhydroxybutyrate (PHB), a homopolymer of R-3-hydroxybutyric acid (R- 3HB) units, are highly crystalline thermoplastic materials, and have been known the longest (Lemoigne & Roukhelman, Annales des fermentations, 5:527-36 (1925)).
  • PHB polyhydroxybutyrate
  • R- 3HB R-3-hydroxybutyric acid
  • the PHA polymers may constitute up to 90% of the dry cell weight of bacteria, and are found as discrete granules inside the bacterial cells. These PHA granules accumulate in response to nutrient limitation and serve as carbon and energy reserve materials. Distinct pathways are used by microorganisms to produce each group of these polymers.
  • SPGPHAs short pendant group polyhydroxyalkanoates
  • One of these pathways leading to the short pendant group polyhydroxyalkanoates (SPGPHAs) involves three enzymes, namely thiolase, reductase and PHB synthase (sometimes called polymerase).
  • the homopolymer PHB is synthesized by condensation of two molecules of acetyl-Coenzyme A to give acetoacetyl-Coenzyme A, followed by reduction of this intermediate to R-3-hydroxybutyryl-Coenzyme A, and subsequent polymerization.
  • the last enzyme in this pathway namely the synthase, has a substrate specificity that can accommodate C3-C5 monomeric units including R-4-hydroxy acid and R-5-hydroxy acid units.
  • This biosynthetic pathway is found, for example, in the bacteria Zoogloea ramigera and Alcaligenes eutrophus.
  • the biosynthetic pathway which is used to make the third group of PHAs namely the long pendant group polyhydroxyalkanoates (LPGPHAs)
  • LPGPHAs long pendant group polyhydroxyalkanoates
  • the R-3-hydroxyacyl-Coenzyme substrates resulting from these routes are then polymerized by PHA synthases (sometimes called polymerases) that have substrate specificities favoring the larger monomeric units in the C6-C14 range.
  • PHA synthases sometimes called polymerases
  • the second group of PHAs containing both short R-3HB units and longer pendant group monomers utilize both the pathways described above to provide the hydroxy acid monomers.
  • the latter are then polymerized by PHA synthases able to accept these units.
  • PHA synthases able to accept these units.
  • these include PHAs containing functionalized pendant groups such as esters, double bonds, alkoxy, aromatic, halogens and hydroxy groups.
  • functionalized pendant groups such as esters, double bonds, alkoxy, aromatic, halogens and hydroxy groups.
  • PHA polymers may also be derived by chemical synthesis.
  • One widely used approach involves the ring-opening polymerization of ⁇ -lactone monomers using various catalysts or initiators such as aluminoxanes, distannoxanes, or alkoxy-zinc and alkoxy-aluminum compounds (see Agostini, et al., Polym.
  • PHA3444 It is a co- polymer of (R)-3 -hydroxybutyrate and 4-hydroxybutyrate.
  • the chemical structure of PHA3444 is shown in Figure IB.
  • PHA3444 is a tough and elastic semi-crystalline polymer. The crystallinity and many mechanical properties of PHA3444 depend upon the ratio of monomers (i.e. percentage of 3 -hydroxybutyrate (3HB or 34 unit) and 4-hydroxybutyrate monomers
  • the percentage of the 4HB or 44 unit can be varied from 1% to 99% depending upon the fermentation conditions used to produce the copolymer.
  • Other copolymers in the PHA family include poly-3- hydroxybutyrate-co-3-hydroxyvalerate (PHBV), poly-hydroxyoctanoate-co- hexanoate (PHO) and poly-4-hydoxybutyrate-co-glycolate (PHA4422).
  • PHBV poly-3- hydroxybutyrate-co-3-hydroxyvalerate
  • PHO poly-hydroxyoctanoate-co- hexanoate
  • PHA4422 poly-4-hydoxybutyrate-co-glycolate
  • PHA3444 to develop controlled release systems for the treatment of osteomyelitis.
  • U.S. Patent No. 6,548,569 to Williams et al discloses different forms of PHA4400 (also known as P4HB) including compression molded porous samples, fibers, foams, coated meshes, and microspheres.
  • the polyhydroxyalkanoate polymers should be biocompatible and biodegradable.
  • the polymers are typically prepared by fermentation.
  • Preferred polymers are poly-4-hydroxybutyrate and copolymers thereof.
  • a preferred copolymer is ⁇ oly-3-hydroxybutyrate-co-4-hydroxybutyrate.
  • examples of these polymers are produced by Tepha, Inc. of Cambridge, MA using transgenic fermentation methods, and have weight average molecular weights in the region of 50,000 to 1,000,000.
  • B. Drugs The drug used in a particular drug release formulation will depend upon the specific treatment. The examples describe antibiotics for treatment or prevention of infection, however, the utility of the polymers shown here are not limited to the use of antibiotics. Other drugs that could be potentially used in a drug release formulation from the polymers described here include medicines for the treatment of disease, injury or pain.
  • the drug can be a protein, peptide, polysaccharide, nucleic acid molecule, or synthetic or natural organic compound.
  • bioactive peptides or proteins such as growth factors, hormones, and cell attachment factors, anti-proliferative agents, antibiotics, chemotherapeutics, anesthetics, small drug molecules, steroids, enzymes, lipids, antigens, antibodies, surfactants, vitamins, flavoring agents, radioactive molecules, sweeteners, nutritional agents, and fragrances.
  • the percentage loading of the drug will also depend on the specific treatment and the desired release kinetics.
  • the polymers are suitable for drug loadings to at least 33% (i.e. polymer to drug ratios of 2:1). When the PHA polymers described here are loaded with drug (2:1), the drug release formulations remained flexible and retained good mechanical properties.
  • the device is characterized by linear or zero-order drug release. In a more preferred embodiment, the device does not release a burst of the drug. Drug will typically be released over a period of at least 21 days, at least one month, at least three months, or at least six months. In general a linear release of drug is preferred.
  • the length of time for the drug release can be controlled by selection of the drug, varying the drug loading and the shape and configuration of the drug release device. The examples show nearly linear release of the antibiotic drugs over a period of 18 days. It is expected that the period of release will extend beyond this time period and can be varied by the device configuration.
  • the drug delivery systems are preferably manufactured by a method that evenly disperses the drug throughout the device, such as solvent casting, spray drying, and melt extrusion. They may also, however, be prepared by other methods such as compression molding and lyophilization.
  • the delivery systems may take virtually any form, including granules, sheets, films, and particles, such as microspheres, nanospheres, microparticles, and microcapsules, as well as molded forms, such as patches, tablets, suspensions, pastes, rods, disks, pellets, and other molded forms.
  • Preferred devices include microspheres and implantable molded devices. Desired release profiles may be further tailored by altering the physical shape of the delivery system. (For example, by altering the surface area or porosity of the device, or by varying the polymer to drug ratio.) Other components may also be introduced into the formulation as necessary to aid or improve delivery, administration, drug release, and/or monitoring.
  • the method of administration of the drug delivery system will be dependent upon the type of drug and its known pharmaceutical properties, and the form of the delivery system.
  • Small devices may be implanted, microspheres may be injected, patches affixed to the skin, and tablets, suspension, and capsules taken orally.
  • Preferred methods of administration are by injection and implantation.
  • these polymers are particularly useful for construction of drug release systems with controllable rates. They are also suitable for loading significantly larger quantities of drug within a typical controlled release sample.
  • Non-limiting examples are given herein to describe the methods for preparing the drug delivery systems, and to illustrate the prolonged drug release profile and high drug loadings that can be achieved.
  • PHA4400 Rod Preparation PHA4400 powder (Tepha, Inc., Cambridge, MA) (Mw -450 K) was weighed, placed in liquid nitrogen to render it brittle, and ground three times in a blender for 5 s duration. Chloroform was added to the resulting granules until a paste was formed, and then an antibiotic drug was added in a 2: 1 ratio of polymer.drug by weight. The paste was then introduced into a mold measuring 150x5x5 mm, and left to dry at ambient temperature. The dry molded formulation was removed from the mold, and sections 2 mm thick were cut yielding rods with approximate dimensions of 2x5x5 mm. Rod samples containing two different forms of tetracycline antibiotic were prepared.
  • EXAMPLE 2 Drug Release from PHA4400 Rods A rod prepared as described in Example 1 was pre-weighed and introduced into a 50 mL Falcon tube containing 30 mL of 0.1 M pH 7.4 PBS (phosphate buffer). The tube was placed in a shaking water bath and maintained at 37 °C. Release of the antibiotic was determined by UN spectrophotometry using the extinction coefficients cited in Example 1 at 4 hours, 24 hours, and then daily with complete replacement of the release buffer with PBS. The release studies were carried out in a minimum of triplicate for each antibiotic.
  • Chloroform was added to the resulting granules until a paste was formed, and then an antibiotic drug was added in a 2:1 ratio of poiyme ⁇ drug by weight.
  • the paste was then introduced into a mold measuring 150x5x5 mm, and left to dry at ambient temperature.
  • the dry molded formulation was removed from the mold, and sections 2 mm thick were cut yielding rods with approximate dimensions of 2x5x5 mm (as in Example 2).
  • Rod samples containing two different forms of tetracycline antibiotic were prepared. These were a highly water soluble HC1 form, designated TC, and a neutral form, designated TCN (as above).
  • EXAMPLE 4 Drug Release from PHA3444-34% Rods A rod prepared as described in Example 3 loaded 2:1 with TC or TCN was pre-weighed and introduced into a 50 mL Falcon tube containing 30 mL of 0.1 M pH 7.4 PBS (phosphate buffer). The tube was placed in a shaking water bath and maintained at 37 °C. Release of the antibiotic was determined by UV spectrophotometry using the extinction coefficients cited in Example 1 at 4 hours, 24 hours, and then daily with complete replacement of the release buffer with PBS. The release studies were carried out in a minimum of triplicate for each antibiotic.
  • Penassay Broth Medium was prepared using the components in Table 1. The medium pH was 7.00 ⁇ 0.05 and the sterilization conditions were 121 °C for 15 min. For solid media, agar (1% w/v) was added prior to sterilization. The bacterial strain E. coli DH5 ⁇ was inoculated to 200 mL broth medium, shaken overnight at 37°C at 200 rpm in an orbital shaker. Inoculate 200 mL bacteria to the plates containing solid Penassay Broth Media. Table 1 : Penassay Broth Medium components
  • Negative Control Applied 25 microliter buffer containing no drug onto the
  • Polymers tested include PHA4400 and PHA3444-34%. The ration of polymer to Tetracycline antibiotic in the test sample rods is provided below each polymer sample. Table 2. Results of the Antibiogram Test

Abstract

Biodegradable controlled release systems providing prolonged controlled release of drugs, and methods for the manufacture thereof are disclosed. The systems are formed from a biocompatible, biodegradable polymer, in particular poly-4-hydroxybutyrate (PHA4400) or copolymers thereof. Copolymers of 4-hydroxybutyrate include but are not limited to poly-3-hydroxybutyrate-co-4-hydroxybutyrate (PHA3444), and poly-4-hydoxybutyrate-co-glycolate (PHA4422). Drugs are generally incorporated into the polymer using a method that yields a uniform dispersion. The type of drug and the quantity are selected based on the known pharmaceutical properties of these compounds. The systems may be administered for example by implantation, injection, topical administration, or oral ingestion. They may also be used in combination with a medical device, for example, a stent. A major advantage of the drug delivery system is that it does not need to be removed after use since it is slowly degraded and cleared by the patient's body. The device has desirable physical properties, including strength, modulus and elongation.

Description

POLY-4-HYDROXYBUTYRATE MATRICES FOR SUSTAINED DRUG DELIVERY Cross-reference to Related Applications This application claims priority to U.S. Serial No. 60/491,430 entitled "Poly-4-Hydroxybutyrate Matrices For Sustained Drug Delivery", filed on
July 30, 2003 by Vasif N. Hasirci and Dilek Sendil Keskin, and U.S. Serial No. 60/485,373 entitled "Polyhydroxyalkanoate Medical Textiles And Fibers", filed July 8, 2003 by Vasif N. Hasirci. Background of the Invention The present invention generally relates to drug delivery systems derived from poly-4-hydroxybutyrate. The use of biodegradable polymers to make drug delivery systems is well established. For example, Takeda Pharmaceuticals has developed a formulation based on polylactide-co-glycolide for the delivery of LHRH (leuteinizing hormone-releasing hormone) that can be administered monthly and provide a prolonged therapeutic level of LHRH for the treatment of prostate cancer, and Guilford Pharmaceuticals has developed a formulation of the cancer chemotherapeutic drug, carmustine (BCNU), sold under the tradename of GLIADEL™, which is based on a degradable polyanhydride polymer. Another company, Atrix Laboratories has developed a system called ATRIDOX™ based on a degradable polylactide (PLA) for the delivery of the antibiotic doxycycline for periodontal therapy. Despite these positive developments there still exists a need to develop new and improved drug delivery systems. Devices based on PLA, for example, have been reported to cause localized inflammation (see U.S Patent No. 6,214,387 to
Berde and Langer). Berde, et al. (Abstracts of Scientific Papers, 1990 Annual Meeting, Amer. Soc. Anesthesiologists, 13: All 6, September 1990) have also reported drawbacks of certain degradable polyanhydride drug delivery systems that include fast initial release of drug, and inflammatory responses to the device or the formation of a capsule of serous material or fibrin. For certain applications, such as the treatment of chronic or persistent pain, long- term contraception or administration of antibiotics, growth factors, or chemotherapeutics, or prevention of restenosis after stent implantation, it would be advantageous to develop systems that can administer drugs for prolonged periods of time. It would also be desirable to develop systems that can be loaded with large amounts of drug to provide prolonged release and/or to permit the use of smaller devices, as well as systems that can deliver different types of drugs (e.g. hydrophobic, hydrophilic, peptides, proteins, DNA and RNA) without decreasing the activity (for example, resulting from the unfolding of an active peptide or protein) of the drug. Accordingly, it is the object of this invention to provide an improved biodegradable controlled release system that administers a drug for a prolonged period of time. It is a further object of this invention to provide an improved biodegradable controlled release system that can be loaded with large amounts of drug. It is yet another object of this invention to provide methods for preparing and modulating the rate of release of the drug from the controlled release system. Summary of the Invention Biodegradable controlled release systems providing prolonged controlled release of drugs, and methods for the manufacture thereof are disclosed. The systems are formed from a biocompatible, biodegradable polymer, in particular poly-4-hydroxybutyrate (PHA440) or copolymers thereof. Copolymers of 4-hydroxybutyrate include but are not limited to poly-3-hydroxybutyrate-co-4-hydroxybutyrate (PHA3444), and poly-4- hydoxybutyrate-co-glycolate (PHA4422). Drugs are generally incorporated into the polymer using a method that yields a uniform dispersion. The type of drug and the quantity are selected based on the known pharmaceutical properties of these compounds. The systems may be administered for example by implantation, injection, topical administration, or oral ingestion. They may also be used in combination with a medical device, for example, a stent. A major advantage of the drug delivery system is that it does not need to be removed after use since it is slowly degraded and cleared by the patient's body. The device has desirable physical properties, including strength, modulus and elongation. Brief Description of the Drawings Figures 1A and IB are the chemical structures of poly-4- hydroxybutyrate (PHA4400) and poly-3-hydroxybutyrate-co-4- hydroxybutyrate (PHA3444). Figure 2 is sdescription of the biosynthetic pathways for the production of PHA4400 (P4HB). Pathway enzymes are: 1. Succinic semialdehyde dehydrogenase, 2. 4-hydroxybutyrate dehydrogenase, 3. diol oxidoreductase, 4. aldehyde dehydrogenase, and 5. Coenzyme A transferase and 6. PHA synthetase. Figures 3 A and 3B are graphs of the release of Tetracycline from PHA4400:TC (2:1) rods (37°C, PBS, 364.0 nm) (n=4). Figure 3A, Average cumalative (%) release vs. time; Figure 3B, Average Cum. (%) release vs. square root time . Figures 4 A and B are graphs of release of Tetracycline (neutral) from PHA4400:TCN (2:1) rods (37°C, PBS, 357.6 nm) (n=4). Figure 4A, Average Cum. (%) release vs. time; Figure 4B, Average Cumulative (%) release vs. square root time. Figures 5 A and 5B are graphs of the release of Tetracycline from
PHA3444-34%:TC (2:1) rods (37°C, PBS, 364.0 nm) (n=4). Figure 5A shows Average Cumulative (%) release versus time; Figure 5B shows Average Cumulative (%) release versus square root time. Figures 6A and 6B are graphs of the release of Tetracycline Neutral (TCN) from PHA3444-34%:TCN (2:1) rods (37°C, PBS, 364.0 nm) (n=4).
Figure 6A shows Average Cumulative (%) release versus time; Figure 6B shows Average Cumulative (%) release versus square root time. Detailed Description of the Invention Biodegradable drug delivery systems for the controlled and prolonged release of drugs are provided. These systems can be used where it is necessary to administer a controlled amount of drug over a prolonged period, and/or to employ a system requiring a high drug loading. I. Definitions Poly-4-hydroxybutyrate means a homopolymer comprising 4- hydroxybutyrate units. It may be referred to as PHA4400 or P4HB. Copolymers of poly-4-hydroxybutyrate mean any polymer comprising 4- hydroxybutyrate with one or more different hydroxy acid units, for example, poly-3-hydroxybutyrate-co-4-hydroxybutyrate (PH3444). Biocompatible refers to materials that are not toxic, and do not elicit severe inflammatory or chronic responses in vivo. Any metabolites of these materials should also be biocompatible. Biodegradation means that the polymer must break down or dissolve away in vivo, preferably in less than two years, and more preferably in less than one year. Biodegradation refers to a process in an animal or human. The polymer may break down by surface erosion, bulk erosion, hydrolysis or a combination of these mechanisms. The term "microspheres" also includes nanospheres, microparticles, and microcapsules. II. Drug Delivery Devices A. Polymers Poly-4-hydroxybutyrate (PHA4400) is a strong, pliable thermoplastic that is produced by a fermentation process (see US Patent No.
6,548,569 to Williams et al.). Despite its biosynthetic route, the structure of the polyester is relatively simple (Figure 1 A). The polymer belongs to a larger class of materials called polyhydroxyalkanoates (PHAs) that are produced by numerous microorganims (for reviews see: Steinbϋchel, A. (1991) Polyhydroxyalkanoic acids, in Biomaterials, (Byrom, D., Ed.), pp.
123-213. New York: Stockton Press; Steinbϋchel, A. and Valentin, H.E. (1995) FEMS Microbial. Lett. 128:219-228; and Doi, Y. (1990) Microbial Polyesters, New York: VCH). Polyhydroxyalkanoates (PHAs) are a class of naturally occurring polyesters that are synthesized by numerous organisms in response to environmental stress. For reviews, see Byrom, Miscellaneous Biomaterials,2 in Byrom, ed., Biomaterials MacMillan Publishers, London, 1991, pp. 333-59; Hocking & Marchessault, 3Biopolyesters2 in Griffin, ed., Chemistry and Technology of Biodegradable Polymers, Chapman and Hall, London, 1994, pp.48-96; Holmes, 3Biologically Produced (%)-3- hydroxyalkanoate Polymers and Copolymers2 in Bassett, ed., Developments in Crystalline Polymers, Elsevier, London, vol. 2, 1988, pp. 1-65; Lafferty et al 3Microbial Production of Poly-β-hydroxybutyric acid2 in Rehm & Reed, eds., Biotechnology. Verlagsgesellschaft, Weinheim, vol. 66, 1988, pp. 135- 76; Mϋller & Seebach, Angew. Chem. Int. Ed. Engl. 32:477-502 (1993); Steinbiichel, 3Polyhydroxyalkanoic Acids2 in Byrom, ed., Biomaterials, MacMillan Publishers, London, 1991, pp. 123-213; Williams & Peoples,
CHEMTECH, 26:38-44, (1996), and the recent review by Madison & Husiman, Microbiol. & Mol. Biol. Rev. 63:21-53 (1999). The PHA biopolymers may be broadly divided into three groups according to the length of their pendant groups and their respective biosynthetic pathways. Those with short pendant groups, such as polyhydroxybutyrate (PHB), a homopolymer of R-3-hydroxybutyric acid (R- 3HB) units, are highly crystalline thermoplastic materials, and have been known the longest (Lemoigne & Roukhelman, Annales des fermentations, 5:527-36 (1925)). A second group of PHAs containing the short R-3HB units randomly polymerized with much longer pendant group hydroxy acid units were first reported in the early seventies (Wallen & Rohwedder, Environ. Sci. Technol, 8:576-79 (1974)). A number of microorganisms which specifically produce copolymers of R-3HB with these longer pendant group hydroxy acid units are also known and belong to this second group (Steinbϋchel & Wiese, Appl. Microbiol. Biotechnol, 37:691 -97 (1992)). In the early eighties, a research group in The Netherlands identified a third group of PHAs, which contained predominantly longer pendant group hydroxy acids (De Smet, et al., J. Bacteriol, 154:870-78 (1983)). The PHA polymers may constitute up to 90% of the dry cell weight of bacteria, and are found as discrete granules inside the bacterial cells. These PHA granules accumulate in response to nutrient limitation and serve as carbon and energy reserve materials. Distinct pathways are used by microorganisms to produce each group of these polymers. One of these pathways leading to the short pendant group polyhydroxyalkanoates (SPGPHAs) involves three enzymes, namely thiolase, reductase and PHB synthase (sometimes called polymerase). Using this pathway, the homopolymer PHB is synthesized by condensation of two molecules of acetyl-Coenzyme A to give acetoacetyl-Coenzyme A, followed by reduction of this intermediate to R-3-hydroxybutyryl-Coenzyme A, and subsequent polymerization. The last enzyme in this pathway, namely the synthase, has a substrate specificity that can accommodate C3-C5 monomeric units including R-4-hydroxy acid and R-5-hydroxy acid units. This biosynthetic pathway is found, for example, in the bacteria Zoogloea ramigera and Alcaligenes eutrophus. The biosynthetic pathway which is used to make the third group of PHAs, namely the long pendant group polyhydroxyalkanoates (LPGPHAs), is still partly unknown, however, it is currently thought that the monomeric hydroxyacyl units leading to the LPGPHAs are derived by the β-oxidation of fatty acids and the fatty acid pathway. The R-3-hydroxyacyl-Coenzyme substrates resulting from these routes are then polymerized by PHA synthases (sometimes called polymerases) that have substrate specificities favoring the larger monomeric units in the C6-C14 range. Long pendant group PHAs are produced, for example, by Pseudomonads. Presumably, the second group of PHAs containing both short R-3HB units and longer pendant group monomers utilize both the pathways described above to provide the hydroxy acid monomers. The latter are then polymerized by PHA synthases able to accept these units. In all about 100 different types of hydroxy acids have been incorporated into PHAs by fermentation methods so far (Williams, et. al, Int. J. Biol Macromol, 25:111-21 (1999)). Notably, these include PHAs containing functionalized pendant groups such as esters, double bonds, alkoxy, aromatic, halogens and hydroxy groups. During the mid- 1980 8, several research groups were actively identifying and isolating the genes and gene products responsible for PHA synthesis. These efforts have lead to the development of transgenic systems for production of PHAs in both microorganism and plants, as well as enzymatic methods for PHA synthesis. Such routes could increase further the available PHA types. These advances have been reviewed in Williams & Peoples, CHEMTECH, 26:38-44 (1996), Madison & Huisman, Microbiol
Mol. Biol Rev., 63:21-53 (1999), and Williams & Peoples, Chem. Br. 33:29- 32 (1997). In addition to using biological routes for PHA synthesis, PHA polymers may also be derived by chemical synthesis. One widely used approach involves the ring-opening polymerization of β-lactone monomers using various catalysts or initiators such as aluminoxanes, distannoxanes, or alkoxy-zinc and alkoxy-aluminum compounds (see Agostini, et al., Polym. Sci, Part A-1, 9:2775-87 (1971); Gross, et al., Macromolecules, 21:2657-68 (1988); Dubois, et al., Macromolecules, 26:4407-12 (1993); Le Borgne & Spassky, Polymer, 30:2312-19 (1989); Tanahashi & Doi, Macromolecules,
24:5732-33 (1991); Hori, et al., Macromolecules, 26:4388-90 (1993); Kemnitzer, et al., Macromolecules, 26:1221-29 (1993); Hori, et al., Macromolecules, 26:5533-34 (1993); Hocking & Marchessault, Polym. Bull, 30:163-70 (1993); U.S. Patent Nos. 5,489,470 and 5,502,116 to Noda). A second approach involves condensation polymerization of esters and is described in U.S. Pat. No. 5,563,239 to Hubbs, et al., and references therein. Researchers also have developed chemo-enzymatic methods to prepare PHAs. Xie et al., Macromolecules, 30:6997-98 (1997), for example, discloses a ring opening polymerization of beta-butyrolactone by thermophilic lipases to yield PHB. Several biosynthetic routes are currently known to produce PHA4400, and these are shown in Figure 2. (Chemical synthesis of PHA4400 has been attempted, but it has been impossible to produce the polymer with a sufficiently high molecular weight necessary for most applications, see Hori, et al (1995) Polymer 36:4703-4705). Poly-3-hydroxybutyrate-co-4-hydroxybutyrate (PHA3444 or P3HB- co-4HB) also belongs to the PHA family of biological polyesters. It is a co- polymer of (R)-3 -hydroxybutyrate and 4-hydroxybutyrate. The chemical structure of PHA3444 is shown in Figure IB. PHA3444 is a tough and elastic semi-crystalline polymer. The crystallinity and many mechanical properties of PHA3444 depend upon the ratio of monomers (i.e. percentage of 3 -hydroxybutyrate (3HB or 34 unit) and 4-hydroxybutyrate monomers
(4HB or 44 unit)) in the polymer. The percentage of the 4HB or 44 unit can be varied from 1% to 99% depending upon the fermentation conditions used to produce the copolymer. Other copolymers in the PHA family include poly-3- hydroxybutyrate-co-3-hydroxyvalerate (PHBV), poly-hydroxyoctanoate-co- hexanoate (PHO) and poly-4-hydoxybutyrate-co-glycolate (PHA4422). Suitable methods for preparing the PHA polyesters are described in Williams, S.F. and Peoples, O.P. CHEMTECH, 26:38-44 (1996), Williams, S.F. and Peoples, O.P., Chem. Br., 33:29-32 (1997), U.S. Patent No. 4,910,145 to Holmes, P.A. and Lim, G.B.; Byrom, D., Miscellaneous
Biomaterials, in D. Byrom, Ed., Biomaterials MacMillan Publishers, London, 1991, pp. 333-359; Hocking, P.J. and Marchessault, R.H. Biopolyesters, G.J.L. Griffin, Ed., Chemistry and Technology of Biodegradable Polymers, Chapman and Hall, London, 1994, pρ.48-96; Holmes, P. A., Biologically Produced (R)-3-hydroxyalkanoate Polymers and
Copolymers, in D.C. Bassett Ed., Developments in Crystalline Polymers, Elsevier, London, Vol. 2, 1988, pp. 1-65; Lafferty et al., Microbial Production of Poly-b-hydroxybutyric acid, H.J. Rehm and G. Reed, Eds., Biotechnology, Verlagsgesellschaft, Weinheim, Vol. 66, 1988, pp. 135-176; Mϋller and Seebach, Angew. Chem. Int. Ed. Engl. 32:477-502 (1993);
Steinbϋchel, A. Polyhydroxyalkanoic Acids, in D. Byrom Ed., Biomaterials, MacMillan Publishers, London, 1991, pp. 123-213; and, Williams and Peoples, CHEMTECH, 26:38-44, (1996); Steinbϋchel and Wiese, Appl. Microbiol. Biotechnol., 37:691-697 (1992); U.S. Patent Nos. 5,245,023; 5,250,430; 5,480,794; 5,512,669; 5,534,432; Agostini, D.E. et al, Polym.
Sci., Part A-1, 9:2775-2787 (1971); Gross, R.A. et al., Macromolecules, 21:2657-2668 (1988); Dubois, P.I. et al., Macromolecules, 26:4407-4412 (1993); Le Borgne, A. and Spassky, N., Polymer, 30:2312-2319 (1989); Tanahashi, N. and Doi, Y., Macromolecules, 24:5732-5733 (1991); Hori, Y.M. et al., Macromolecules, 26:4388-4390 (1993); Kemnitzer, J.E. et al., Macromolecules, 26:1221-1229 (1993); Hori, Y.M. et al., Macromolecules, 26:5533-5534 (1993); Hocking, P.J. and Marchessault, R.H., Polym. Bull,
30:163-170 (1993); Xie, W. et al., Macromolecules, 30:6997-6998 (1997), U.S. Pat. No. 5,563,239 to Hubbs, J.C. and Harrison, M.N., and Braunegg, G. et al, J. Biotechnol. 65:127-161 (1998). Tepha, Inc. (Cambridge, MA) produces PHA4400 and PHA 3444 for the development of medical uses, and has filed separate Device Master Files with the United States Food and Drug Administration (FDA) for PHA4400 and PHA3444. Methods to control molecular weight of PHA polymers have been disclosed by US Patent No. 5,811,272 to Snell et al, and methods to purify PHA polymers for medical use have been disclosed by U.S Patent No. 6,245,537 to Williams et al. PHAs with degradation rates in vivo of less than one year have been disclosed by US Patent No. 6,548,569 to Williams et al. and PCT WO 99/32536 to Martin et al. The use of PHAs to produce a range of medical devices has been disclosed. For example, US Patent No. 6,514,515 to Williams discloses tissue engineering scaffolds, US Patent No. 6,555,123 to Williams and
Martin discloses soft tissue repair, augmentation and viscosupplementation, PCT WO 01/15671 to Williams discloses flushable disposable polymeric products, and PCT WO 01/19361 to Williams and Martin discloses PHA prodrug therapeutic compositions. Other applications of PHAs have been reviewed by Williams, S.F. and Martin, D.P. (2002) Applications of PHAs in medicine and pharmacy, in Biopolymers: Polyesters, III (Doi, Y. and Steinbϋchel, A., Eds.) vol. 4, pp. 91-127. Weinheim: Wiley- VCH. Several reports have described the use of copolymers of 4- hydroxybutyrate with 3 -hydroxybutyrate (PHA3444) to develop drug delivery systems. For example, Gϋrsel, et al. (2001) Biomaterials 22:73-80,
Korkusuz, et al. (2001) J. Biomed. Mater. Res. 55:217-228, and Tϋresin et al (2001) J. Biomater. Sci. Polymer Edn. 12:195-207 have described the use of PHA3444 to develop controlled release systems for the treatment of osteomyelitis. U.S. Patent No. 6,548,569 to Williams et al discloses different forms of PHA4400 (also known as P4HB) including compression molded porous samples, fibers, foams, coated meshes, and microspheres. The polyhydroxyalkanoate polymers should be biocompatible and biodegradable. The polymers are typically prepared by fermentation. Preferred polymers are poly-4-hydroxybutyrate and copolymers thereof. A preferred copolymer is ρoly-3-hydroxybutyrate-co-4-hydroxybutyrate. Examples of these polymers are produced by Tepha, Inc. of Cambridge, MA using transgenic fermentation methods, and have weight average molecular weights in the region of 50,000 to 1,000,000. B. Drugs The drug used in a particular drug release formulation will depend upon the specific treatment. The examples describe antibiotics for treatment or prevention of infection, however, the utility of the polymers shown here are not limited to the use of antibiotics. Other drugs that could be potentially used in a drug release formulation from the polymers described here include medicines for the treatment of disease, injury or pain. The drug can be a protein, peptide, polysaccharide, nucleic acid molecule, or synthetic or natural organic compound. These include but are not limited to bioactive peptides or proteins, such as growth factors, hormones, and cell attachment factors, anti-proliferative agents, antibiotics, chemotherapeutics, anesthetics, small drug molecules, steroids, enzymes, lipids, antigens, antibodies, surfactants, vitamins, flavoring agents, radioactive molecules, sweeteners, nutritional agents, and fragrances. The percentage loading of the drug will also depend on the specific treatment and the desired release kinetics. The polymers are suitable for drug loadings to at least 33% (i.e. polymer to drug ratios of 2:1). When the PHA polymers described here are loaded with drug (2:1), the drug release formulations remained flexible and retained good mechanical properties.
Higher loadings of up to 1:1 also can be used and show good mechanical properties. The desired release kinetics will also depend upon the specific treatment. In a preferred embodiment, the device is characterized by linear or zero-order drug release. In a more preferred embodiment, the device does not release a burst of the drug. Drug will typically be released over a period of at least 21 days, at least one month, at least three months, or at least six months. In general a linear release of drug is preferred. The length of time for the drug release can be controlled by selection of the drug, varying the drug loading and the shape and configuration of the drug release device. The examples show nearly linear release of the antibiotic drugs over a period of 18 days. It is expected that the period of release will extend beyond this time period and can be varied by the device configuration.
III. Method of Manufacture The drug delivery systems are preferably manufactured by a method that evenly disperses the drug throughout the device, such as solvent casting, spray drying, and melt extrusion. They may also, however, be prepared by other methods such as compression molding and lyophilization. The delivery systems may take virtually any form, including granules, sheets, films, and particles, such as microspheres, nanospheres, microparticles, and microcapsules, as well as molded forms, such as patches, tablets, suspensions, pastes, rods, disks, pellets, and other molded forms. Preferred devices include microspheres and implantable molded devices. Desired release profiles may be further tailored by altering the physical shape of the delivery system. (For example, by altering the surface area or porosity of the device, or by varying the polymer to drug ratio.) Other components may also be introduced into the formulation as necessary to aid or improve delivery, administration, drug release, and/or monitoring.
IV. Method of Administration The method of administration of the drug delivery system will be dependent upon the type of drug and its known pharmaceutical properties, and the form of the delivery system. Small devices may be implanted, microspheres may be injected, patches affixed to the skin, and tablets, suspension, and capsules taken orally. Preferred methods of administration are by injection and implantation. As demonstrated by the examples, these polymers are particularly useful for construction of drug release systems with controllable rates. They are also suitable for loading significantly larger quantities of drug within a typical controlled release sample. Non-limiting examples are given herein to describe the methods for preparing the drug delivery systems, and to illustrate the prolonged drug release profile and high drug loadings that can be achieved. EXAMPLE 1: PHA4400 Rod Preparation PHA4400 powder (Tepha, Inc., Cambridge, MA) (Mw -450 K) was weighed, placed in liquid nitrogen to render it brittle, and ground three times in a blender for 5 s duration. Chloroform was added to the resulting granules until a paste was formed, and then an antibiotic drug was added in a 2: 1 ratio of polymer.drug by weight. The paste was then introduced into a mold measuring 150x5x5 mm, and left to dry at ambient temperature. The dry molded formulation was removed from the mold, and sections 2 mm thick were cut yielding rods with approximate dimensions of 2x5x5 mm. Rod samples containing two different forms of tetracycline antibiotic were prepared. These were a highly water soluble HC1 form, designated TC, and a neutral form, designated TCN (FAKO Pharmaceutical Co., Istanbul). Extinction coefficients for these two forms were determined as 0.117 (μg/mL)"1 at 364 nm for TC and 0.145 (μg/mL)"1 at 357.6 nm for TCN at 37°C. Rods containing 10:1 and 5:1 ratios of PHA4400 to drug were also prepared as described above.
EXAMPLE 2: Drug Release from PHA4400 Rods A rod prepared as described in Example 1 was pre-weighed and introduced into a 50 mL Falcon tube containing 30 mL of 0.1 M pH 7.4 PBS (phosphate buffer). The tube was placed in a shaking water bath and maintained at 37 °C. Release of the antibiotic was determined by UN spectrophotometry using the extinction coefficients cited in Example 1 at 4 hours, 24 hours, and then daily with complete replacement of the release buffer with PBS. The release studies were carried out in a minimum of triplicate for each antibiotic. The release behavior appeared to follow Higuchi release kinetics (the k values for TC and TCN were 7.79 and 2.62, respectively) for an 11-day period releasing only a fraction of the total content, see Figures 3 and 4. TC released at a higher rate than the less water soluble TCN. The average cumulative release of TC at 11 days was approximately 25% versus 9% for TCN, demonstrating long term or sustained release. Release from polymer loaded 10:1 was also determined. Release PHA4400 loaded 10:1 with TC showed zero order release over a period of about 15 days, with a minor short burst initially, possibly due to remnants of drug crystals left on the surface during drying. Release of TCN showed no burst, and almost perfect zero order release after the first hour, with a total of 17% in fifteen days, indicating that drug release should continue for several months. Release from polymer loaded 5:1 was similar, with a slighter higher level of release and shorter duration compared to the 10:1 loaded system. EXAMPLE 3: PHA3444 Rod Preparation PHA3444 (34% 44) powder (Tepha, Inc., Cambridge, MA) (Mw -477 K) was weighed, placed in liquid nitrogen to render it brittle, and ground three times in a blender for 5 s duration. Chloroform was added to the resulting granules until a paste was formed, and then an antibiotic drug was added in a 2:1 ratio of poiymeπdrug by weight. The paste was then introduced into a mold measuring 150x5x5 mm, and left to dry at ambient temperature. The dry molded formulation was removed from the mold, and sections 2 mm thick were cut yielding rods with approximate dimensions of 2x5x5 mm (as in Example 2). Rod samples containing two different forms of tetracycline antibiotic were prepared. These were a highly water soluble HC1 form, designated TC, and a neutral form, designated TCN (as above). EXAMPLE 4: Drug Release from PHA3444-34% Rods A rod prepared as described in Example 3 loaded 2:1 with TC or TCN was pre-weighed and introduced into a 50 mL Falcon tube containing 30 mL of 0.1 M pH 7.4 PBS (phosphate buffer). The tube was placed in a shaking water bath and maintained at 37 °C. Release of the antibiotic was determined by UV spectrophotometry using the extinction coefficients cited in Example 1 at 4 hours, 24 hours, and then daily with complete replacement of the release buffer with PBS. The release studies were carried out in a minimum of triplicate for each antibiotic. The release behavior appeared to follow Higuchi release kinetics (the k values for TC and TCN were 17.45 and 5.62, respectively) for an 18-day period releasing only a fraction of the total content, see Figures 5 A and 5B and 6A and 6B. TC released at a higher rate than the less water soluble TCN. The average cumulative release of TC at 17 days was approximately 65% versus 23% for TCN. No burst of release was observed with either TC or TCN. Similar results were obtained with PHA3444-50% (PHA3444 containing 50% 44 monomer) PHA polymer loaded 2:1, however, with a short burst releasing almost 25% of the drug. A total of 60% of the TC is released in 15 days, 62% in 23 days, with the release versus time square root plot yielding a straight line as expected from a monolithic release device. Results were not greatly different using a PHA3444-23% (PHA3444 containing 23% 44 monomer) loaded 2:1 with TC or TCN EXAMPLE 5: Biological Effectiveness of Released Antibiotic In this Example, the antibiotic properties of the Tetracycline released from the PHA rods was determined in an in vitro biological assay against E. coli DH5α. For this in vitro bioassay, the Agar Diffusion Method was used and the size of a zone of clearing was determined after applying the antibiotic solution to a petri dish grown with a lawn of E.Coli DH5α. All the steps of this procedure were carried out under aseptic conditions. Penassay Broth Medium was prepared using the components in Table 1. The medium pH was 7.00 ± 0.05 and the sterilization conditions were 121 °C for 15 min. For solid media, agar (1% w/v) was added prior to sterilization. The bacterial strain E. coli DH5α was inoculated to 200 mL broth medium, shaken overnight at 37°C at 200 rpm in an orbital shaker. Inoculate 200 mL bacteria to the plates containing solid Penassay Broth Media. Table 1 : Penassay Broth Medium components
On the next day, the TC solutions (25 μL), collected at I Sst , ~ 7rth and
14t days (release product of the last 24 hours) and sterilized by a microfilter, were applied to sterile filter discs. Two discs containing TC solutions were placed onto each plate and maintained at 37°C for 24 hours. The radius of the clearing zone was determined in mm. The results are shown in Table 2.
The results for clearing zones for the tetracycline released from rod made of the PHA3444-23% and PHA3444-50% polymers were similar to that of the
PHA3444-34% polymer, but are not shown in Table 2.
Negative Control: Applied 25 microliter buffer containing no drug onto the
Petri plate
Positive Control: Applied 25 microliter buffer containing 10 mg TC/mL onto the Petri plate
Polymers tested include PHA4400 and PHA3444-34%. The ration of polymer to Tetracycline antibiotic in the test sample rods is provided below each polymer sample. Table 2. Results of the Antibiogram Test

Claims

We claim: 1. A biodegradable controlled release drug delivery system comprising drug uniformly distributed in poly-4-hydroxybutyrate wherein the drug is incorporated into the polymer at a percent loading of up to 50% by weight of the device.
2. The drug delivery system of claim 1 wherein less than 60% of the drug is released in vitro after 10 days.
3. The drug delivery system of claim 1 wherein less than 35% of the drug is released in vitro after 10 days.
4. The drug delivery system of claim 1 wherein the drug is selected from the group consisting of proteins, peptides, polysaccharides, nucleic acid molecules, and synthetic or natural organic compounds.
5. The drug delivery system of claim 4 wherein the drug is an antibiotic.
6. The drug delivery system of claim 1 wherein the drug is coated onto a medical device.
7. The drug delivery system of claim 1 wherein the device is formed of the poly-4-hydroxybutyrate or copolymer thereof.
8. The drug delivery system of claim 1 wherein the poly-4- hydroxybutyrate or a copolymer thereof is formed of or coated onto a stent.
9. The drug delivery system of claim 1 in a form selected from the group consisting of granules, sheets, films, particles, and molded forms.
10. The drug delivery system of claim 1 wherein the copolymer is a copolymer of 3 -hydroxybutyrate and 4-hydroxybutyrate.
11. The drug delivery system of claim 1 wherein the copolymer is a copolymer of 4-hydroxybutyrate and glycolate.
12. The drug delivery system of claim 1 wherein the device exhibits linear release of the drug.
13. The drug delivery system of claim 1 wherein the device exhibits zero-order release of the drug.
14. The drug delivery system of claim 1 wherein the device does not release a burst of drug.
15. The drug delivery system of claim 1 wherein the device releases drug for at least 21 days 16. The drug delivery system of claim 1 wherein the device releases drug for at least one month. 17. The drug delivery system of claim 1 wherein the device releases drug for at least three months. 18. The drug delivery system of claim 1 wherein the device releases drug for at least six months. 19. A method of delivering a drug comprising administering to an individual in need thereof the device of any of claims 1-18.
EP04777860A 2003-07-08 2004-07-08 Poly-4-hydroxybutyrate matrices for sustained drug delivery Active EP1651273B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48537303P 2003-07-08 2003-07-08
US49143003P 2003-07-30 2003-07-30
PCT/US2004/022040 WO2005007195A1 (en) 2003-07-08 2004-07-08 Poly-4-hydroxybutyrate matrices for sustained drug delivery

Publications (2)

Publication Number Publication Date
EP1651273A1 true EP1651273A1 (en) 2006-05-03
EP1651273B1 EP1651273B1 (en) 2012-08-29

Family

ID=34083339

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04777860A Active EP1651273B1 (en) 2003-07-08 2004-07-08 Poly-4-hydroxybutyrate matrices for sustained drug delivery

Country Status (7)

Country Link
US (1) US20050025809A1 (en)
EP (1) EP1651273B1 (en)
JP (1) JP2007528853A (en)
AU (1) AU2004257701B2 (en)
CA (1) CA2531833C (en)
ES (1) ES2395077T3 (en)
WO (1) WO2005007195A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318833B2 (en) * 2001-12-19 2008-01-15 Nmt Medical, Inc. PFO closure device with flexible thrombogenic joint and improved dislodgement resistance
EP1467661A4 (en) * 2001-12-19 2008-11-05 Nmt Medical Inc Septal occluder and associated methods
CA2471871A1 (en) * 2002-01-14 2003-07-24 Nmt Medical, Inc. Patent foramen ovale (pfo) closure method and device
WO2003082076A2 (en) * 2002-03-25 2003-10-09 Nmt Medical, Inc. Patent foramen ovale (pfo) closure clips
WO2003103476A2 (en) 2002-06-05 2003-12-18 Nmt Medical, Inc. Patent foramen ovale (pfo) closure device with radial and circumferential support
WO2004037333A1 (en) 2002-10-25 2004-05-06 Nmt Medical, Inc. Expandable sheath tubing
CA2503349A1 (en) * 2002-11-06 2004-05-27 Nmt Medical, Inc. Medical devices utilizing modified shape memory alloy
EP1572003B1 (en) * 2002-12-09 2017-03-08 W.L. Gore & Associates, Inc. Septal closure devices
US8480706B2 (en) * 2003-07-14 2013-07-09 W.L. Gore & Associates, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US9861346B2 (en) 2003-07-14 2018-01-09 W. L. Gore & Associates, Inc. Patent foramen ovale (PFO) closure device with linearly elongating petals
ES2428967T3 (en) * 2003-07-14 2013-11-12 W.L. Gore & Associates, Inc. Oval foramen tubular permeable closure device (FOP) with retention system
US7963952B2 (en) * 2003-08-19 2011-06-21 Wright Jr John A Expandable sheath tubing
US20050273119A1 (en) 2003-12-09 2005-12-08 Nmt Medical, Inc. Double spiral patent foramen ovale closure clamp
JP2007526087A (en) * 2004-03-03 2007-09-13 エヌエムティー メディカル, インコーポレイティッド Delivery / recovery system for septal occluder
US20050267524A1 (en) * 2004-04-09 2005-12-01 Nmt Medical, Inc. Split ends closure device
US8361110B2 (en) * 2004-04-26 2013-01-29 W.L. Gore & Associates, Inc. Heart-shaped PFO closure device
US7842053B2 (en) * 2004-05-06 2010-11-30 Nmt Medical, Inc. Double coil occluder
US8308760B2 (en) * 2004-05-06 2012-11-13 W.L. Gore & Associates, Inc. Delivery systems and methods for PFO closure device with two anchors
WO2005110240A1 (en) 2004-05-07 2005-11-24 Nmt Medical, Inc. Catching mechanisms for tubular septal occluder
CA2581677C (en) * 2004-09-24 2014-07-29 Nmt Medical, Inc. Occluder device double securement system for delivery/recovery of such occluder device
WO2006102213A1 (en) 2005-03-18 2006-09-28 Nmt Medical, Inc. Catch member for pfo occluder
US20070167981A1 (en) * 2005-12-22 2007-07-19 Nmt Medical, Inc. Catch members for occluder devices
JP2009532125A (en) * 2006-03-31 2009-09-10 エヌエムティー メディカル, インコーポレイティッド Deformable flap catch mechanism for occluder equipment
US8870913B2 (en) 2006-03-31 2014-10-28 W.L. Gore & Associates, Inc. Catch system with locking cap for patent foramen ovale (PFO) occluder
US8551135B2 (en) 2006-03-31 2013-10-08 W.L. Gore & Associates, Inc. Screw catch mechanism for PFO occluder and method of use
US20080082083A1 (en) * 2006-09-28 2008-04-03 Forde Sean T Perforated expandable implant recovery sheath
US7943683B2 (en) * 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US9005242B2 (en) 2007-04-05 2015-04-14 W.L. Gore & Associates, Inc. Septal closure device with centering mechanism
US7897168B2 (en) * 2007-04-13 2011-03-01 Medtronic Vascular, Inc. Degradable polymers incorporating gamma-butyrolactone
US9138562B2 (en) 2007-04-18 2015-09-22 W.L. Gore & Associates, Inc. Flexible catheter system
US20130165967A1 (en) 2008-03-07 2013-06-27 W.L. Gore & Associates, Inc. Heart occlusion devices
US9216152B2 (en) * 2008-06-27 2015-12-22 Tepha, Inc. Injectable delivery of microparticles and compositions therefore
US9492375B2 (en) * 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
GB2470378A (en) * 2009-05-20 2010-11-24 Univ Westminster A controlled release composition for intraocular delivery of a therapeutic agent
US9636094B2 (en) 2009-06-22 2017-05-02 W. L. Gore & Associates, Inc. Sealing device and delivery system
US20120029556A1 (en) 2009-06-22 2012-02-02 Masters Steven J Sealing device and delivery system
US8475824B2 (en) 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US8758791B2 (en) 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US8734488B2 (en) 2010-08-09 2014-05-27 Ellipse Technologies, Inc. Maintenance feature in magnetic implant
WO2012064526A1 (en) 2010-11-09 2012-05-18 Tepha, Inc. Drug eluting cochlear implants
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
CA2838317C (en) * 2011-06-28 2016-02-09 Nippon Soda Co., Ltd. Calcium hypochlorite composition
US9770232B2 (en) 2011-08-12 2017-09-26 W. L. Gore & Associates, Inc. Heart occlusion devices
WO2013176734A1 (en) 2012-05-21 2013-11-28 Tepha, Inc. Resorbable bioceramic compositions of poly-4-hydroxybutyrate and copolymers
US10828019B2 (en) 2013-01-18 2020-11-10 W.L. Gore & Associates, Inc. Sealing device and delivery system
US9302029B2 (en) * 2013-10-31 2016-04-05 Tepha, Inc. Pultrusion of poly-4-hydroxybutyrate and copolymers thereof
US9808230B2 (en) 2014-06-06 2017-11-07 W. L. Gore & Associates, Inc. Sealing device and delivery system
ES2802383T3 (en) 2014-09-22 2021-01-19 Tepha Inc Targeted P4HB implants containing antimicrobial agents
US11559604B2 (en) 2017-08-31 2023-01-24 University Of Westminster Nerve conduits
WO2019112925A1 (en) 2017-12-04 2019-06-13 Tepha, Inc. Vacuum membrane thermoformed poly-4-hydroxybutyrate medical implants

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4205399A (en) * 1977-06-13 1980-06-03 Ethicon, Inc. Synthetic absorbable surgical devices of poly(alkylene oxalates)
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
EP0104731B1 (en) * 1982-08-27 1987-11-25 Imperial Chemical Industries Plc 3-hydroxybutyrate polymers
US4856188A (en) * 1984-10-12 1989-08-15 Drug Delivery Systems Inc. Method for making disposable and/or replenishable transdermal drug applicators
EP0145233B2 (en) * 1983-11-23 1991-11-06 Imperial Chemical Industries Plc Separation processfor a 3-hydroxybutyrate polymer
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
GB8424950D0 (en) * 1984-10-03 1984-11-07 Ici Plc Non-woven fibrous materials
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4648978A (en) * 1985-04-24 1987-03-10 American Sterilizer Company Process for the continuous preparation of sterile, depyrogenated solutions
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
FI75493C (en) * 1985-05-08 1988-07-11 Materials Consultants Oy SJAELVARMERAT ABSORBERBART PURCHASING SYNTHESIS.
AU603076B2 (en) * 1985-12-09 1990-11-08 W.R. Grace & Co.-Conn. Polymeric products and their manufacture
US4758234A (en) * 1986-03-20 1988-07-19 Norman Orentreich High viscosity fluid delivery system
US4664655A (en) * 1986-03-20 1987-05-12 Norman Orentreich High viscosity fluid delivery system
US5032638A (en) * 1986-09-05 1991-07-16 American Cyanamid Company Bioabsorbable coating for a surgical device
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
JPH0725689B2 (en) * 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
NL8603073A (en) * 1986-12-02 1988-07-01 Rijksuniversiteit METHOD FOR PREPARING POLYESTERS BY FERMENTATION; METHOD FOR PREPARING OPTICALLY ACTIVE CARBONIC ACIDS AND ESTERS; POLYESTER INCLUDING PRODUCTS.
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5059211A (en) * 1987-06-25 1991-10-22 Duke University Absorbable vascular stent
US5245023A (en) * 1987-06-29 1993-09-14 Massachusetts Institute Of Technology Method for producing novel polyester biopolymers
US5480794A (en) * 1987-06-29 1996-01-02 Massachusetts Institute Of Technology And Metabolix, Inc. Overproduction and purification of soluble PHA synthase
US5229279A (en) * 1987-06-29 1993-07-20 Massachusetts Institute Of Technology Method for producing novel polyester biopolymers
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5085629A (en) * 1988-10-06 1992-02-04 Medical Engineering Corporation Biodegradable stent
US5026381A (en) * 1989-04-20 1991-06-25 Colla-Tec, Incorporated Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit
US5041100A (en) * 1989-04-28 1991-08-20 Cordis Corporation Catheter and hydrophilic, friction-reducing coating thereon
US5002067A (en) * 1989-08-23 1991-03-26 Medtronic, Inc. Medical electrical lead employing improved penetrating electrode
DE59003337D1 (en) * 1989-10-16 1993-12-09 Danubia Petrochem Polymere Pressling with delayed release of active ingredient.
JPH0662839B2 (en) * 1989-11-14 1994-08-17 工業技術院長 Microbial degradable plastic molding and method for producing the same
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
AU636481B2 (en) * 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
IT1247157B (en) * 1991-02-11 1994-12-12 Fidia Spa BIODEGRADABLE AND BIOABSORBABLE GUIDE CHANNELS TO BE USED FOR NERVE REGENERATION.
DE4113984C2 (en) * 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salts of 4-hydroxy butyric acid
FR2676927B1 (en) * 1991-05-29 1995-06-23 Ibf MICROSPHERES FOR USE IN THERAPEUTIC VASCULAR OCCLUSIONS AND INJECTABLE SOLUTIONS CONTAINING THEM.
US5236431A (en) * 1991-07-22 1993-08-17 Synthes Resorbable fixation device with controlled stiffness for treating bodily material in vivo and introducer therefor
JP2777757B2 (en) * 1991-09-17 1998-07-23 鐘淵化学工業株式会社 Copolymer and method for producing the same
EP0560984B1 (en) * 1991-09-27 1999-05-26 Terumo Kabushiki Kaisha Flexible member for medical use
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US5204382A (en) * 1992-02-28 1993-04-20 Collagen Corporation Injectable ceramic compositions and methods for their preparation and use
CH689767A5 (en) * 1992-03-24 1999-10-15 Balzers Hochvakuum Process for Werkstueckbehandlung in a Vakuumatmosphaere and vacuum treatment system.
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5278256A (en) * 1992-09-16 1994-01-11 E. I. Du Pont De Nemours And Company Rapidly degradable poly (hydroxyacid) compositions
GB9223350D0 (en) * 1992-11-06 1992-12-23 Ici Plc Polymer composition
GB9223351D0 (en) * 1992-11-06 1992-12-23 Ici Plc Polyesters
JP3263710B2 (en) * 1992-12-11 2002-03-11 高砂香料工業株式会社 Biodegradable optically active polymer and method for producing the same
US5443458A (en) * 1992-12-22 1995-08-22 Advanced Cardiovascular Systems, Inc. Multilayered biodegradable stent and method of manufacture
US5288516A (en) * 1993-02-11 1994-02-22 E. I. Du Pont De Nemours And Company Process of producing bioabsorbable filaments
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5412067A (en) * 1993-05-10 1995-05-02 Mitsui Toatsu Chemicals, Inc. Preparation process of polyester
GB9311402D0 (en) * 1993-06-02 1993-07-21 Zeneca Ltd Processing of polyesters
US5874040A (en) * 1993-06-02 1999-02-23 Monsanto Company Processing of polyesters
JP3243334B2 (en) * 1993-06-10 2002-01-07 テルモ株式会社 Hydroxyalkanoate polymer composition
ATE149349T1 (en) * 1993-06-25 1997-03-15 Alza Corp INCORPORATING A POLY-N-VINYLAMIDE INTO A TRANSDERMAL SYSTEM
JPH083333A (en) * 1994-06-22 1996-01-09 Tokuyama Corp Melt-extruded film of biodegradable aliphatic polyester and bag comprising the same
WO1995018781A1 (en) * 1994-01-06 1995-07-13 Metabolix, Inc. Methods for synthesizing oligomers containing hydroxy acid units
ZA95627B (en) * 1994-01-28 1995-10-05 Procter & Gamble Biodegradable copolymers and plastic articles comprising biodegradable copolymers
NZ279627A (en) * 1994-01-28 1998-06-26 Procter & Gamble Article comprising poly(3-hydroxyhexanoate)copolymerised with a 3- or 4-hydroxycarboxylic acid
DK0952792T3 (en) * 1994-06-06 2003-12-08 Osiris Therapeutics Inc Biomatrix for tissue regeneration
US5629077A (en) * 1994-06-27 1997-05-13 Advanced Cardiovascular Systems, Inc. Biodegradable mesh and film stent
BR9508583A (en) * 1994-08-12 1998-07-14 Minnesota Mining & Mfg Pressure sensitive adhesive composition of pressure sensitive adhesive article and process of adhering two substrates
JP3790567B2 (en) * 1994-09-30 2006-06-28 武田薬品工業株式会社 Sustained release agent
US5599852A (en) * 1994-10-18 1997-02-04 Ethicon, Inc. Injectable microdispersions for soft tissue repair and augmentation
US5879322A (en) * 1995-03-24 1999-03-09 Alza Corporation Self-contained transdermal drug delivery device
DE19539449A1 (en) * 1995-10-24 1997-04-30 Biotronik Mess & Therapieg Process for the production of intraluminal stents from bioresorbable polymer material
JP3369421B2 (en) * 1996-12-18 2003-01-20 理化学研究所 Film composed of poly (3-hydroxybutanoic acid)
IL132120A0 (en) * 1997-04-03 2001-03-19 Guilford Pharm Inc Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
US6245537B1 (en) * 1997-05-12 2001-06-12 Metabolix, Inc. Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation
US6610764B1 (en) * 1997-05-12 2003-08-26 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
US5876455A (en) * 1997-07-24 1999-03-02 Harwin; Steven F. Bio-shim
WO1999032536A1 (en) * 1997-12-22 1999-07-01 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
JPH11199514A (en) * 1998-01-13 1999-07-27 Meiji Seika Kaisha Ltd Sustainably releasing pharmaceutically prepared composition
US6056970A (en) * 1998-05-07 2000-05-02 Genzyme Corporation Compositions comprising hemostatic compounds and bioabsorbable polymers
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
FR2784580B1 (en) * 1998-10-16 2004-06-25 Biosepra Inc POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME
WO2000051662A1 (en) * 1999-03-04 2000-09-08 Tepha, Inc. Bioabsorbable, biocompatible polymers for tissue engineering
ES2295021T3 (en) * 1999-03-25 2008-04-16 Metabolix, Inc. USE AND MEDICAL APPLICATIONS OF POLYMER POLYMERS (HYDROXIALCANOATS).
US6103255A (en) * 1999-04-16 2000-08-15 Rutgers, The State University Porous polymer scaffolds for tissue engineering
US7025980B1 (en) * 1999-09-14 2006-04-11 Tepha, Inc. Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation
WO2001019361A2 (en) * 1999-09-14 2001-03-22 Tepha, Inc. Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
US20020168518A1 (en) * 2001-05-10 2002-11-14 The Procter & Gamble Company Fibers comprising starch and polymers
US20050107505A1 (en) * 2002-02-05 2005-05-19 Hosei Shinoda Biodegradable resin composition and molded object thereof
US6838492B2 (en) * 2002-06-17 2005-01-04 Scentco, Llc. Scented paints, paint scenting additive mixtures and processes for producing scented paints
EP1778305B1 (en) * 2004-08-03 2010-07-07 Tepha, Inc. Non-curling polyhydroxyalkanoate sutures

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005007195A1 *

Also Published As

Publication number Publication date
EP1651273B1 (en) 2012-08-29
JP2007528853A (en) 2007-10-18
WO2005007195A1 (en) 2005-01-27
ES2395077T3 (en) 2013-02-08
AU2004257701A1 (en) 2005-01-27
US20050025809A1 (en) 2005-02-03
AU2004257701B2 (en) 2007-09-13
CA2531833A1 (en) 2005-01-27
CA2531833C (en) 2009-10-20

Similar Documents

Publication Publication Date Title
CA2531833C (en) Poly-4-hydroxybutyrate matrices for sustained drug delivery
AU751610B2 (en) Polyhydroxyalkanoate compositions having controlled degradation rates
US6610764B1 (en) Polyhydroxyalkanoate compositions having controlled degradation rates
US6867248B1 (en) Polyhydroxyalkanoate compositions having controlled degradation rates
US6828357B1 (en) Polyhydroxyalkanoate compositions having controlled degradation rates
JP4975782B2 (en) Bioabsorbable polymer containing 2-hydroxy acid monomer
EP0981381B1 (en) Polyhydroxyalkanoates for in vivo applications
AU780953B2 (en) Flushable disposable polymeric products
Jirage et al. Poly-βhydroxybutyrate: intriguing biopolymer in biomedical applications and pharma formulation trends
EP1339776B1 (en) Polyanhydrides
Somerville Williams et al.
GÜRSEL et al. Biodegradable polyhydroxyalkanoate implants for osteomyelitis therapy: in vitro antibiotic release

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20071123

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TEPHA, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 572697

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004039151

Country of ref document: DE

Effective date: 20121025

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 572697

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120829

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2395077

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121130

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121231

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121129

26N No opposition filed

Effective date: 20130530

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004039151

Country of ref document: DE

Effective date: 20130530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130708

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20040708

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230620

Year of fee payment: 20

Ref country code: FR

Payment date: 20230621

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230620

Year of fee payment: 20

Ref country code: ES

Payment date: 20230801

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230620

Year of fee payment: 20